Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera BCR-ABL Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy N/A

    BCR-ABL Kinase Inhibitors

    Customize your policy alerts

    Sign up for all Premera Bluecross policy alerts

    Know when Premera Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This clinical medical policy governs coverage of BCR-ABL kinase inhibitors used in oncology treatment. It is intended for providers and is administered under a prior-authorization program.

    Policy Summary
    PayerPremera Bluecross
    PolicyBCR-ABL Kinase Inhibitors
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit office visit notes documenting the diagnosis, relevant history, physical evaluation, medication history, and medical necessity criteria.
    SourceLink
    POLICY UPDATE CHANGES

    The 2016 update removed the Zytiga (abiraterone acetate) step requirement for Xtandi (enzalutamide).

    The 2018 update added Yonsa (abiraterone) coverage criteria and incorporated Erleada into updated product labeling and NCCN recommendations.

    The 2019 update added coverage criteria for Nubeqa (darolutamide) and expanded Erleada coverage to metastatic castration-sensitive prostate cancer.

    The 2021 update added the requirement that generic abiraterone, Zytiga, Yonsa, Nubeqa, and Erleada be used in combination with androgen deprivation therapy.

    Added coverage criteria for Abirtega, generic abiraterone, and Zytiga for metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient when used with capivasertib.

    Removed references to non-formulary exception reviews.

    Added Akeega coverage for deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer when used with prednisone.

    Updated the initial authorization period for all other reviews of oral drugs in the policy from 3 months to 6 months.

    Removed radium Ra 223 from this policy because it moved to Policy 6.01.525 Therapeutic Radiopharmaceuticals in Oncology.

    7Oral drugs managed through the pharmacy benefit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1Intravenous drug managed through the medical benefit
    6 monthsMaximum initial authorization
    12 monthsMaximum reauthorization
    Not Medicare AdvantageScope exclusion

    Coverage Criteria

    Abirtega (abiraterone) initial therapy

    Abirtega (abiraterone) may be considered medically necessary when all criteria are met.

    Abirtega criteria

    • Diagnosis

      • Metastatic castration-resistant prostate cancer (CRPC)
      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy
    • Combination therapy: Abirtega is used in combination with prednisone

    Akeega (niraparib and abiraterone acetate) initial therapy

    Akeega (niraparib and abiraterone acetate) may be considered medically necessary for adults when all criteria are met.

    Akeega criteria

    • Diagnosis

      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer
      • Deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy

    Erleada (apalutamide) initial therapy

    Erleada (apalutamide) may be considered medically necessary when all criteria are met.

    Erleada criteria

    • Diagnosis

      • Metastatic castration-sensitive prostate cancer
      • Non-metastatic castration-resistant prostate cancer
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy

    Nubeqa (darolutamide) initial therapy

    Nubeqa (darolutamide) may be considered medically necessary when all criteria are met.

    Nubeqa criteria

    • Diagnosis and treatment setting

      • Non-metastatic castration-resistant prostate cancer
      • Metastatic castration-sensitive prostate cancer
      • Metastatic castration-sensitive prostate cancer in combination with docetaxel
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog

    Xtandi (enzalutamide) initial therapy

    Xtandi (enzalutamide) may be considered medically necessary when all criteria are met.

    Xtandi criteria

    • Diagnosis and treatment setting

      • Castration-resistant prostate cancer
      • Metastatic castration-sensitive prostate cancer
      • HRR gene-mutated metastatic castration-resistant prostate cancer in combination with Talzenna (talazoparib)
      • Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis
    • Androgen deprivation therapy documentation

    Yonsa (abiraterone) initial therapy

    Yonsa (abiraterone) may be considered medically necessary when all criteria are met.

    Yonsa criteria

    • Diagnosis: Metastatic castration-resistant prostate cancer
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy
    • Combination therapy: Yonsa is used in combination with methylprednisolone or another corticosteroid

    Zytiga (abiraterone) initial therapy

    Zytiga (abiraterone) may be considered medically necessary when all criteria are met.

    Zytiga criteria

    • Diagnosis and treatment setting

      • Metastatic castration-resistant prostate cancer
      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer when used in combination with Lynparza (olaparib)
      • Metastatic high-risk castration-sensitive prostate cancer
      • Metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient when used in combination with capivasertib

    Jevtana (cabazitaxel) initial therapy

    Jevtana (cabazitaxel) may be considered medically necessary when all stated criteria are met.

    Jevtana criteria

    • Metastatic castration-resistant prostate cancer
    • Jevtana is used in combination with prednisone
    • The individual has been previously treated with a docetaxel-based regimen. The source text truncates the final prior-treatment criterion after ‘docetaxel-’.

    Continuation therapy

    Reauthorization requires continued drug-specific eligibility and clinical benefit.

    Continuation therapy: Drug-specific coverage criteria remain met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.Up to 12 months

    Abiraterone products for PTEN-deficient mAPMN/S prostate cancer

    Coverage applies when all criteria are met.

    PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer

    • The individual has metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient
    • Treatment with Abirtega, generic abiraterone, or Zytiga is used in combination with capivasertib

    Akeega for BRCA2-mutated mCSPC

    Akeega coverage includes this indication when all criteria are met.

    BRCA2-mutated metastatic castration-sensitive prostate cancer

    • The individual has deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer
    • Akeega is used in combination with prednisone

    All other uses of the medications listed in this policy are considered investigational and are not covered under the policy’s medically necessary indications.

    This medical policy does not apply to Medicare Advantage.

    Coding

    HCPCSHCPCSCovered
    J9043Injection, cabazitaxel (Jevtana), 1 mg
    Historical code referencesHCPCS
    A9606Radium (Ra) 223
    J9043Code added with coverage criteria for Jevtana (cabazitaxel)

    Provider Actions

    Prior Authorization

    Initial Authorization

    Submit the request for initial authorization for the applicable drug. Initial authorization may be approved for up to 6 months.

    Prior Authorization

    Reauthorization Requires Documented Response

    Request reauthorization when the drug-specific coverage criteria continue to be met and the chart documents that the individual continues to show a positive clinical response. Reauthorization may be approved for up to 12 months.

    Billing Rule

    Policy Background

    This policy addresses BCR-ABL kinase inhibitors, a class of targeted oncology therapies. No additional clinical background or disease-specific explanation is identified in the policy.

    Definitions

    Castration-Resistant Prostate Cancer
    TermCastration-resistant prostate cancer (CRPC)
    Disease courseProstate cancer that has progressed despite local therapy and first-line hormonal therapy.
    Testosterone statusProgression occurs while testosterone remains at castrate levels.
    Metastatic Castration-Resistant Prostate Cancer
    TermMetastatic castration-resistant prostate cancer (mCRPC)
    Treatment responseDisease is resistant to androgen deprivation therapy.
    Disease extent

    Initial Therapy Criteria

    Abirtega (abiraterone) initial therapy

    Abirtega may be considered medically necessary when all criteria are met.

    Abirtega criteria

    • Diagnosis

      • Metastatic castration-resistant prostate cancer
      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog

    Continuation Criteria

    All listed drugs — continuation and reauthorization

    All drugs listed in this policy may be approved for reauthorization for up to 12 months when the following criteria are met.

    Reauthorization: Drug-specific coverage criteria remain met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.Up to 12 months

    Step Therapy

    StepRequested medicationRequirement before coverage
    1Yonsa (abiraterone)Trial of Abirtega (abiraterone) or generic abiraterone with an inadequate response or intolerance
    StepRequested medicationRequirement before coverage
    1Zytiga (abiraterone)Trial of Abirtega (abiraterone) or generic abiraterone with an inadequate response or intolerance
    Treatment history or intoleranceSubsequent treatment options
    mCRPC recurring after abiraterone or enzalutamide, or intolerance to those therapiesDocetaxel; the alternate androgen-directed therapy (abiraterone or enzalutamide); olaparib for HRR-mutated disease; radium-223 for symptomatic bone metastases; sipuleucel-T; other secondary hormone therapy; or a clinical trial
    Treatment history or intoleranceSubsequent treatment options
    mCRPC recurring after docetaxel, or intolerance to docetaxelAbiraterone; enzalutamide; cabazitaxel; radium-223 for symptomatic bone metastases; mitoxantrone; other secondary hormone therapy; sipuleucel-T; or a clinical trial
    Policy Summary
    PayerPremera Bluecross
    PolicyBCR-ABL Kinase Inhibitors
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit office visit notes documenting the diagnosis, relevant history, physical evaluation, medication history, and medical necessity criteria.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider ActionsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy
    Combination therapy: Akeega is used in combination with prednisone
    Prior bilateral orchiectomy
    Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
  1. Prior bilateral orchiectomy
  2. Prior therapy: The individual has tried and had an inadequate response or intolerance to Abirtega (abiraterone) or generic abiraterone
    Prior therapy:
    The individual has tried and had an inadequate response or intolerance to Abirtega (abiraterone) or generic abiraterone
  3. Androgen deprivation therapy documentation

    • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
    • Prior bilateral orchiectomy
  4. Combination therapy: Zytiga is used in combination with prednisone
  5. Use the Correct Benefit

    Apply the correct benefit pathway when submitting the request.

    • Oral drugs are managed through the pharmacy benefit.
    • Jevtana (cabazitaxel) is managed through the medical benefit.
    Prior Authorization

    Oral Drug Prior Authorization

    Oral drugs are subject to the prior-authorization program. The updated initial authorization period for oral drugs is up to 6 months.

    • Submit the required clinical information for prior-authorization review.
    • Confirm that the requested use meets the applicable drug-specific criteria.
    Step Therapy

    Yonsa Prerequisite Therapy

    Before requesting Yonsa, document that the individual tried Abirtega (abiraterone) or generic abiraterone and had an inadequate response or intolerance.

    • Include the prior treatment, outcome, and reason for inadequate response or intolerance.
    Step Therapy

    Zytiga Prerequisite Therapy

    Before requesting Zytiga, document that the individual tried Abirtega (abiraterone) or generic abiraterone and had an inadequate response or intolerance.

    • Include the prior treatment, outcome, and reason for inadequate response or intolerance.
    Documentation Required

    Submit Required Clinical Records

    Submit medical records that establish medical necessity and show that the applicable coverage criteria are met.

    • Office visit notes with the diagnosis, relevant history, physical evaluation, and medication history.
    • Include other records needed to support the requested therapy and its medical necessity.
    Documentation Required

    Support Drug-Specific Criteria

    Include drug-specific documentation with each request, as applicable, to establish the diagnosis and required treatment combination or status.

    • Document the applicable prostate cancer diagnosis and disease setting.
    • Document ADT through concurrent GnRH-analog therapy or prior bilateral orchiectomy when required.
    • Document required combination therapy, including prednisone, methylprednisolone or another corticosteroid, docetaxel, capivasertib, or Talzenna as applicable.
    • Document prior treatment and response or intolerance when required.
    Documentation Required

    Document the HRR Mutation

    For Talzenna treatment of HRR gene-mutated metastatic castration-resistant prostate cancer, document the applicable HRR gene mutation.

    • Applicable mutations include ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C.
    Denial Risk

    Investigational Uses Are Not Covered

    All other uses of the medications listed in this policy are considered investigational and are not covered as medically necessary.

    • Confirm that the requested indication is one of the covered uses in the policy and is consistent with the product's FDA dosage and administration prescribing information.
    Denial Risk

    Meet All Drug-Specific Criteria

    Coverage depends on meeting the individual drug's applicable criteria. Failure to document a required diagnosis, combination therapy, ADT, corticosteroid use, prior treatment, or other condition may result in non-approval.

    • Verify the diagnosis and disease setting.
    • Document required ADT and combination therapy.
    • Document required corticosteroid therapy and prerequisite treatment history.
    Denial Risk

    Document Positive Response for Reauthorization

    For reauthorization, submit chart notes showing a positive clinical response and continued eligibility under the drug-specific coverage criteria.

    • Document the individual's response to therapy.
    • Document that all continuing coverage requirements remain satisfied.
    Denial Risk

    Capivasertib Required for PTEN-Deficient Disease

    For PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer, the requested abiraterone-containing therapy must be used in combination with capivasertib.

    • Requests for this indication without capivasertib may be denied.
    Denial Risk

    Akeega Requires Prednisone Combination

    For Akeega treatment of BRCA2-mutated metastatic castration-sensitive prostate cancer, document use in combination with prednisone.

    • Also document the applicable BRCA2 mutation, mCSPC diagnosis, and ADT when required.
    Cancer has spread to other parts of the body.
    Metastatic Castration-Sensitive Prostate Cancer
    TermMetastatic castration-sensitive prostate cancer (mCSPC)
    Disease extentProstate cancer has spread to distant or other parts of the body.
    Treatment responseDisease remains sensitive to androgen deprivation or other androgen-directed treatment.
    Androgen Deprivation Therapy
    TermAndrogen deprivation therapy (ADT)
    Medical ADTConcurrent treatment with a gonadotropin-releasing hormone (GnRH) analog.
    Surgical ADTPrior bilateral orchiectomy qualifies as androgen deprivation therapy.
    Castration-Resistant Prostate Cancer
    TermCastration-resistant prostate cancer (CRPC)
    ProgressionProstate cancer has progressed despite local therapy and first-line hormonal therapy.
    Castrate statusTestosterone remains at castrate levels.
    Metastatic Castration-Resistant Prostate Cancer
    TermMetastatic castration-resistant prostate cancer (mCRPC)
    Underlying diseaseCastration-resistant prostate cancer.
    Metastatic diseaseDistant metastatic disease is present.
    HRR Gene-Mutated Disease
    TermHRR gene-mutated (HRRm)
    Genetic findingA homologous recombination repair gene alteration is present.
    Testing basisThe alteration is identified through an approved genetic or tumor testing assay, including circulating tumor DNA or solid tumor tissue testing.
    HRR-Mutated Metastatic Castration-Sensitive Prostate Cancer
    TermHRRm mCSPC
    Disease stateMetastatic castration-sensitive prostate cancer.
    Biomarker statusA homologous recombination repair gene mutation is present.
    Metastatic Castration-Sensitive Prostate Cancer
    TermMetastatic castration-sensitive prostate cancer (mCSPC)
    Disease extentDisease is metastatic.
    Treatment responseDisease remains sensitive to androgen deprivation.
    NCCN Category 1
    TermNCCN Category 1
    Evidence basisThe recommendation is based on high-level evidence, such as randomized controlled trials.
    ConsensusThere is uniform consensus among the NCCN panel.
    NCCN Category 2A
    TermNCCN Category 2A
    Evidence basisThe recommendation is based on lower-level evidence.
    ConsensusThere is uniform consensus among the NCCN panel.
    Homologous Recombination Repair Gene Mutation
    DefinitionAn HRR gene mutation is an alteration in a gene involved in homologous recombination repair.
    Listed genesATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, and FANCA.
    Listed genes (continued)MLH1, MRE11A, NBN, PALB2, and RAD51C.
    Prior bilateral orchiectomy
  6. Combination therapy: Abirtega is used in combination with prednisone
  7. Akeega (niraparib and abiraterone acetate) initial therapy for adults

    Akeega may be considered medically necessary for adults when all criteria are met.

    Akeega criteria

    • Diagnosis

      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer
      • Deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy
    • Combination therapy: Akeega is used in combination with prednisone

    Erleada (apalutamide) initial therapy

    Erleada may be considered medically necessary when all criteria are met.

    Erleada criteria

    • Diagnosis

      • Metastatic castration-sensitive prostate cancer
      • Non-metastatic castration-resistant prostate cancer
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy

    Nubeqa (darolutamide) initial therapy

    Nubeqa may be considered medically necessary when all criteria are met.

    Nubeqa criteria

    • Diagnosis and treatment setting

      • Non-metastatic castration-resistant prostate cancer
      • Metastatic castration-sensitive prostate cancer
      • Metastatic castration-sensitive prostate cancer in combination with docetaxel
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy

    Xtandi (enzalutamide) initial therapy

    Xtandi may be considered medically necessary when all criteria are met.

    Xtandi criteria

    • Diagnosis and treatment setting

      • Castration-resistant prostate cancer
      • Metastatic castration-sensitive prostate cancer
      • HRR gene-mutated metastatic castration-resistant prostate cancer in combination with Talzenna (talazoparib)
      • Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy

    Yonsa (abiraterone) initial therapy

    Yonsa may be considered medically necessary when all criteria are met.

    Yonsa criteria

    • Metastatic castration-resistant prostate cancer
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy
    • Yonsa is used in combination with methylprednisolone or another corticosteroid
    • The individual has tried and had an inadequate response or intolerance to Abirtega (abiraterone) or generic abiraterone

    Zytiga (abiraterone) initial therapy

    Zytiga may be considered medically necessary when all criteria are met.

    Zytiga criteria

    • Diagnosis and treatment setting

      • Metastatic castration-resistant prostate cancer
      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer when used in combination with Lynparza (olaparib)
      • Metastatic high-risk castration-sensitive prostate cancer
      • Metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient when used in combination with capivasertib
    • The individual has tried and had an inadequate response or intolerance to Abirtega (abiraterone) or generic abiraterone
    • Androgen deprivation therapy documentation

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog
      • Prior bilateral orchiectomy
    • Zytiga is used in combination with prednisone

    Jevtana (cabazitaxel) initial therapy

    Jevtana may be considered medically necessary when all stated criteria are met.

    Jevtana criteria

    • Metastatic castration-resistant prostate cancer
    • Jevtana is used in combination with prednisone
    • The individual has been previously treated with a docetaxel-based regimen. The source text truncates the final prior-treatment criterion after ‘docetaxel-’.